Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by S. Ekberg
Secondary malignancies in mantle cell lymphoma patients-A nationwide population‐based study in Sweden
Introduction: With modern treatments, mantle cell lymphoma (MCL) patients may experience long-lasting remission resulting in a growing population of long-term survivors. Follow-up care includes identification and management of treatment-related late effects, such as secondary malignancies (SM). We conducted a population-based study to describe the burden of SM in MCL patients in Sweden.
Timing of disease progression and impact on survival in Swedish mantle cell lymphoma patients-a novel illness‐death model study
Background: In mantle cell lymphoma (MCL), time to relapse is a critical factor, and patients experiencing disease progression within 24 months from treatment start (POD24) have inferior survival. However, the cut-off at 24 months is arbitrary and potentially overly simplified. We aimed to quantify the impact of the timing of disease progression on overall survival, stratified by the most common first-line treatment concepts (Nordic-MCL, R-Bendamustin, and R-CHOP).
British Journal of Dermatology
黑色素瘤是最致命的皮肤癌。本次研究在澳大利亚进行,在该国 2016 年有 1,281 人死于黑色素瘤。近几年,随着免疫和靶向治疗技术的引入,黑色素瘤治疗快速变化。因此使某些患者生存期延长,但这些治疗对哪些患者有效,以及有效时间多长尚不明确。本次研究旨在了解黑色素瘤治疗对家属照顾者的经验的影响,因为治疗与诊断和预后相关。对在3个澳大利亚黑色素瘤中心接受治疗并随后死亡的患者的20名照顾者进行了访谈。研究发现,晚期黑色素瘤的诊断有一段不确定时间,因为照顾者努力了解诊断的含义。相对较新的免疫和靶向治疗形式的治疗选项为预后增加了不确定性(即,可能的结局,如存活几率)。照顾者称与医疗专家就预后的沟通不明确。某些照顾者称医疗专家不想或无法提供预后描述。许多照顾者期望治疗会有积极的结局。研究结果显示,医疗专家应该在诊断后尽早识别并解决照顾者对预后信息的了解和需求。就上述新疗法针对不确定疗效的沟通会帮助患者和照顾者对治疗首选项和照顾计划进行决策。
Qualitative study of bereaved carers’ experiences in advanced melanoma
Plain Language Summary Qualitative study of bereaved carers’ experiences in advanced melanoma PDF PDF Share Summary Melanoma is the deadliest form of skin cancer. In Australia, where this study was conducted, there were 1,281 deaths from melanoma in 2016. Treatments for melanoma have changed rapidly in recent years with the introduction of immune and targeted therapies.
Uncertain diagnosis and prognosis in advanced melanoma: A qualitative study of the experiences of bereaved carers in a time of immune and targeted therapies - Fox - - British Journal of Dermatology - Wiley Online Library
Background Recent advances in advanced melanoma therapies are associated with improved survival for some patients. How patients with diagnoses of advanced disease and their carers experience this expanding treatment paradigm, however, is not well understood. Objectives We explored bereaved carers’ accounts of the trajectory of advanced melanoma involving treatment by immune or targeted therapies to build an understanding of their experiences of care relating to diagnosis and prognosis.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with S.
Contact S., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack